CSL Total Non-Operating Income/Expense 2017-2024 | CSLLY

CSL total non-operating income/expense for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.

  • CSL annual total non-operating income/expense for 2024 was $-0.437B, a 7.64% increase from 2023.
  • CSL annual total non-operating income/expense for 2023 was $-0.406B, a 176.19% increase from 2022.
  • CSL annual total non-operating income/expense for 2022 was $-0.147B, a 11.92% decline from 2021.

CSL Total Non-Operating Income/Expense 2017-2024 | CSLLY

  • CSL annual total non-operating income/expense for 2024 was $-0.437B, a 7.64% increase from 2023.
  • CSL annual total non-operating income/expense for 2023 was $-0.406B, a 176.19% increase from 2022.
  • CSL annual total non-operating income/expense for 2022 was $-0.147B, a 11.92% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$214.8B
Amgen (AMGN)$160.4B
Gilead Sciences (GILD)$135.3B
Vertex Pharmaceuticals (VRTX)$119B
Bristol Myers Squibb (BMY)$97.8B
GSK (GSK)$74.7B
Regeneron Pharmaceuticals (REGN)$59.4B
Alnylam Pharmaceuticals (ALNY)$42.3B
Argenex SE (ARGX)$35B
BioNTech SE (BNTX)$26.7B
Royalty Pharma (RPRX)$19.9B
Insmed (INSM)$19.8B
Biogen (BIIB)$18.9B
Illumina (ILMN)$15.5B
Genmab (GNMSF)$14.5B
Genmab (GMAB)$14.1B
Incyte (INCY)$13.3B
Moderna (MRNA)$12.5B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.2B
Ascendis Pharma (ASND)$10.8B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Exact Sciences (EXAS)$9.8B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.9B
Legend Biotech (LEGN)$7.7B
Regencell Bioscience Holdings (RGC)$7.3B